posted
October 25, 2005 - 7:00 AM EDT DNAG 0.0148 N/A
Today 5d 1m 3m 1y 5y 10y
DNAPrint genomics Licenses Ritalin-Like Compounds Targeting Enhanced Treatment of Drug Addiction and Attention Deficit DNAPrint genomics, Inc. (OTC BB: DNAG) today announced it has licensed a series of methylphenidate analogs or Ritalin(TM)-like compounds targeting the clinical development of enhanced pharmaceuticals for the treatment of drug addiction, attention deficit hyperactivity disorder (ADHD), and depression. This is the second drug project that will be developed by DNAPrint Pharmaceuticals. Inc., the Company's wholly owned, recently formed pharmaceutical subsidiary focused on personalized medicine.
The licensed compounds are analogs of Ritalin(TM), a well-known drug used for treatment of ADHD. The analogs are designed specifically to have a slow onset and increased half-life in the blood stream, thus reducing a patient's required daily dosage and the potential for drug abuse.
Methylphenidate was first introduced in the 1940s for patients suffering from narcolepsy, a sleeping disorder. Methylphenidate later was found to be useful in treating hyperactive children and adults with depression. One of the drawbacks for methylphenidate is the requirement for multiple daily doses because the drug reaches peak plasma concentrations in two hours and the half-life is only one to three hours, with 80% of the drug excreted during urination. Dosing starts out low and is gradually escalated to a maximum of 60 mg per day for children.
"Our methylphenidate analogs are designed to treat depression and hyperactivity while reducing the required dosing and mitigating significantly the potential for abuse. Additionally, the compounds have potential as treatments for cocaine abuse. In fact, the National Institute for Drug Abuse is advancing one of the compounds in its search for pharmaco-therapies for cocaine abuse," said Dr. Mark Froimowitz, the leading researcher from whom the technology was licensed. "These compounds were designed using molecular modeling and synthesized in a process developed by Dr. Charles Kelley. This research has come out of 25 years of work in the fields of drug addiction, Parkinson's disease and ADHD."
Drs. Froimowitz and Kelley have applied for patents for the newly licensed compounds.
Ritalin(TM) or methylphenidate analogs represent a $4.6 billion dollar market opportunity by 2014, according to the consulting and research firm Decision Resources, Inc. "That's a significant opportunity for DNAPrint genomics and other drug developers," said Richard Gabriel, President and Chief Executive Officer of the Company. "The unique properties of these new compounds coupled with DNAPrint's expertise in determining the inherited gene characteristics of potential patients will enable us to target research on a drug for patients who respond positively to treatment, and hopefully, develop new compounds for those who might reject such a drug."
Dr. Froimowitz and DNAPrint genomics are also working with the National Institute for Drug Abuse (NIDA) in identifying compounds that offer potential relief to the craving usually associated with drug abuse.
"One of the underlying goals is to utilize the newly licensed Froimowitz analogs to develop drugs for patients who do not respond to methylphenidate treatment at all," said Dr. Hector J. Gomez, DNAPrint's Chief Medical Officer. "We are all very excited about combining our ability to identify responder and non-responder patients using genetic ancestry and other clinical markers and target clinical development programs toward those patients."
About DNAPrint genomics, Inc.
DNAPrint genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services focused on drug development, pharmacogenomic diagnostic tests, forensics technology and consumer genetic tests. The Company's first theranostic product (drug/test combination) is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Currently in pre-clinical development, PT-401 will be targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint's family of products for the law enforcement forensics and consumer markets include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM).
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
Source: Market Wire (October 25, 2005 - 7:00 AM EDT)
posted
DNAPrint genomics Receives Notice of Allowance for Patent for Processing Gene Sequence Data 10/27/05
SARASOTA, Fla., Oct 27, 2005 (PRIMEZONE via COMTEX) -- DNAPrint genomics, Inc. (OTCBB:DNAG), a developer of genomics-based products and services, today announced that it has been granted a notice of allowance from the U.S. Patent and Trademark Office for its patent application for Efficient Methods and Apparatus for High-Throughput Processing of Gene Sequence Data.
"Though we are all 99.9% identical at the level of our DNA, it is the 0.1% difference called polymorphism that accounts for our individuality," stated Tony N. Frudakis, Ph.D., DNAPrint's founder and Chief Scientific Officer. "The technology our patent application covers relates to methods useful for measuring polymorphisms in and around genes that are part of large gene families, a task that traditionally has been problematic for the molecular genetics community."
Geneticists use "molecular addresses" to query and study specific genes much like a postman uses a street address to find the recipient of a letter. The methods covered in the patent are useful when there are several genes with the same or substantially similar "sequence" addresses. Many of the genes that are involved in drug metabolism and response are members of large gene families.
This is the first patent for which the Company applied. The methods covered in the application, first drafted in 2001, were originally developed to power DNAPrint's unique approach to pharmacogenomics research, which is aimed at understanding why people respond uniquely to drugs.
About DNAPrint genomics, Inc.
DNAPrint genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services focused on drug development, pharmacogenomic diagnostic tests, forensics technology and consumer genetic tests. The Company's first theranostic product (drug/test combination) is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Currently in pre-clinical development, PT-401 will be targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint's family of products for the law enforcement forensics and consumer markets include DNAWITNESS, RETINOME, ANCESTRYbyDNA and EURO-DNA.
Posts: 1364 | From: Somebody from Europe | Registered: Sep 2005
| IP: Logged |
posted
SARASOTA, FL, Nov 01, 2005 (MARKET WIRE via COMTEX) -- DNAPrint(TM) genomics, Inc. (OTC BB: DNAG), a developer of genomics-based products and services, today announced that it has acquired Kenna Technologies, Inc., of West Chester, Pa., a private company which builds computer models that mimic complex biological systems.
Under terms of the agreement, Kenna's shareholders exchanged all of the company's outstanding shares for 1.5 million shares of DNAPrint genomics Common Stock. The transaction was effective on Tuesday, Oct. 25, 2005.
"The acquisition of Kenna and its computational biology process, provides substantial synergies with our pharmacogenomics applications," stated Hector J. Gomez, M.D., Ph.D., Chairman and Chief Medical Officer of DNAPrint genomics. "We believe Kenna's technologies will lead to shorter and less expensive drug development times, and represent a powerful tool in our company's search to develop programs for personalized medicine, and test/drug combinations targeting a specific group of patients."
Computational biology models (also called In silico technology,) incorporate the vast datasets and fragmented knowledge of experimentalists and can be a crucial requirement when developing effective therapies and diagnostic products.
"Initially, the Kenna team will support the clinical development of DNAPrint's PT-401 Super EPO erythropoietin dimer for the treatment of anemia and renal failure," stated Kenna co-founder Barbara Handelin, Ph.D, who joins DNAPrint as Director of Diagnostics and General Manager of Computational Biology. "We will provide simulations to help design optimal clinical trials with respect to dosing, patient selection factors and trial duration."
As a result of the acquisition, DNAPrint also gains access to Kenna's BoneFusion(TM) and CellCycleFusion(TM) models. BoneFusion simulates the processes in bone remodeling that underlie diseases like osteoporosis, while CellCycleFusion simulates the molecular pathways that control basic cellular functions. These pathways are common targets of current cancer therapies.
"Simply put, DNAPrint will utilize computational modeling to develop drugs more efficiently," said DNAPrint President and Chief Executive Officer Richard Gabriel. "It will play a valuable role in our Company's efforts to pursue the development of drugs which maximize efficacy and minimize side effects by tailoring medications for specific individuals and well-defined population sectors."
About DNAPrint
DNAPrint genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services focused on drug development, pharmacogenomic diagnostic tests, forensics technology and consumer genetic tests. The Company's first theranostic product (drug/test combination) is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Currently in pre-clinical development, PT-401 will be targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint's family of products for the law enforcement forensics and consumer markets include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM).
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
Company Contact:
Richard Gabriel
President and CEO
941-366-3400
-or-
Ron Stabiner
The Wall Street Group, Inc.
212-888-4848
SOURCE: DNAprint Genomics, Inc.
-------------------- Army guy just trying to make a few bucks.... Posts: 293 | From: Rhode Island | Registered: Oct 2005
| IP: Logged |
posted
DNAPrint Genomics Executives to Attend World Drug Discovery & Development Conference in Copenhagen 11/4/05
SARASOTA, FL, Nov 04, 2005 (MARKET WIRE via COMTEX) -- DNAPrint(TM) genomics, Inc. (OTC BB: DNAG), a developer of genomics-based products and services, today announced that it will be participating in the World Drug Discovery & Development Summit on Tuesday and Wednesday, Nov. 29-30, 2005 in Copenhagen, Denmark.
"The Summit comes at a time when DNAPrint genomics is actively pursuing the development of pharmacogenomic products that include test/drug combinations based on inherited gene characteristics. These test/drug combinations are designed to optimize patient response and improve efficacy," stated Hector J. Gomez, M.D., Ph.D., the Company's Chairman and Chief Medical Officer. "The Summit is an excellent opportunity to participate in targeted meetings with pharmaceutical industry representatives and to discuss our Company's advances in the field of personalized medicine."
Other top DNAPrint executives attending the summit, which is sponsored by the London-based World Trade Group, are President and Chief Executive Office Richard Gabriel and Company Founder and Chief Scientific Officer Tony N. Frudakis.
"This conference presents us a forum to showcase not only our drug development, but also how our technologies, products and services can help the pharmaceutical companies accelerate their own research and development programs," Mr. Gabriel said.
"The development of pharmaceuticals that improve the quality of life for medical patients has been an over-riding goal of our Company from its beginning," Dr. Frudakis stated. "Our research in drug development is well under-way and our newly formed DNAPrint Pharmaceutical subsidiary emphasizes the importance we place on this objective."
Posts: 1364 | From: Somebody from Europe | Registered: Sep 2005
| IP: Logged |
posted
Just saw this. More people hearing about DNAG!
OTC ADVISORS, LLC: www.otc-advisors.com "BULLS IN THE STABLE" CEOA, DNAG, IVCM, MOBL
By M2 Last Update: 11/4/2005 10:33:23 AM Data provided by
NY, Nov 04, 2005 (M2 PRESSWIRE via COMTEX) -- www.otc-advisors.com "Bull's in the stable" CEO America, Inc. (CEOA), DNAPrint(TM)genomics, Inc. (DNAG),IVI Communications Inc. (IVCM) and MobilePro Corp. (MOBL)
Posts: 11 | Registered: Oct 2005
| IP: Logged |
posted
Where do you guys seeing this one going? Is it just having it's day in the sun because of news and then it's bye bye again?
Posts: 1031 | Registered: Sep 2005
| IP: Logged |